Inflammation-related biomarkers as predictors of pathological complete response in early-stage breast cancer.

IF 2.8 3区医学 Q2 ONCOLOGY

Clinical & Translational Oncology Pub Date : 2024-12-12 DOI:10.1007/s12094-024-03814-9

Oraianthi Fiste, Evangelos Mavrothalassitis, Alexandros Kokkalis, Maximilian Anagnostakis, Georgia Gomatou, Athanasios Kontogiannis, Dimitra Karaviti, Eleftheria Karaviti, Nikolaos Konstantinos Syrigos, Athanasios Kotsakis, Elias Alexandros Kotteas

{"title":"Inflammation-related biomarkers as predictors of pathological complete response in early-stage breast cancer.","authors":"Oraianthi Fiste, Evangelos Mavrothalassitis, Alexandros Kokkalis, Maximilian Anagnostakis, Georgia Gomatou, Athanasios Kontogiannis, Dimitra Karaviti, Eleftheria Karaviti, Nikolaos Konstantinos Syrigos, Athanasios Kotsakis, Elias Alexandros Kotteas","doi":"10.1007/s12094-024-03814-9","DOIUrl":null,"url":null,"abstract":"Background: Neoadjuvant systemic therapy (NAT) represents an attractive option for improved outcomes of early-stage breast cancer (BC) patients, as it can significantly reduce tumor burden thus permitting breast-conserving resections. Equally important, the eradication of viable cancer cells post-NAT, also known as pathological complete response (pCR), has emerged as a strong prognostic biomarker, reflecting tumor's biology and subsequent treatment responses. Yet to date, no validated markers predictive of pCR have been identified.Methods: The present retrospective study aimed to explore the value of neutrophil-tolymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as potential predictors of pCR.Results: Despite no statistically significant associations have been reported, NLR and PLR dynamics during NAT, as longitudinal inflammatory phenotypes, merit further investigation in larger cohorts.Conclusion: In the future, the integration of a comprehensive inflammatory biomarker panel into clinical practice could assist in a priori treatment selection process.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-024-03814-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Neoadjuvant systemic therapy (NAT) represents an attractive option for improved outcomes of early-stage breast cancer (BC) patients, as it can significantly reduce tumor burden thus permitting breast-conserving resections. Equally important, the eradication of viable cancer cells post-NAT, also known as pathological complete response (pCR), has emerged as a strong prognostic biomarker, reflecting tumor's biology and subsequent treatment responses. Yet to date, no validated markers predictive of pCR have been identified.

Methods: The present retrospective study aimed to explore the value of neutrophil-tolymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as potential predictors of pCR.

Results: Despite no statistically significant associations have been reported, NLR and PLR dynamics during NAT, as longitudinal inflammatory phenotypes, merit further investigation in larger cohorts.

Conclusion: In the future, the integration of a comprehensive inflammatory biomarker panel into clinical practice could assist in a priori treatment selection process.

查看原文本刊更多论文

背景：新辅助全身治疗（NAT）是改善早期乳腺癌（BC）患者预后的一个有吸引力的选择，因为它可以显著减轻肿瘤负担，从而允许保乳切除。同样重要的是，NAT 后有活力癌细胞的根除（也称为病理完全反应（pCR））已成为一个强有力的预后生物标志物，反映了肿瘤的生物学特性和后续治疗反应。然而，迄今为止，尚未发现可预测病理完全反应的有效标志物：本回顾性研究旨在探讨中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）作为pCR潜在预测指标的价值：结果：尽管没有统计学意义上的关联报道，但作为纵向炎症表型，NAT期间的NLR和PLR动态值得在更大的队列中进一步研究：结论：在未来，将全面的炎症生物标志物面板整合到临床实践中有助于先验性治疗选择过程。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.